Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | SLC26A6 | Q9BXS9 | 10/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10871495 | 0.73 | FABP3 (0.34) | KDM4EALDH1A1FABP3FABP4FABP5 | |
| SCHEMBL1472014 | 0.70 | NR3C1 (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL17267977 | 0.70 | SMN1; SMN2 (0.35) | SMN1; SMN2TP53KDM4EALDH1A1HPGD | |
| SCHEMBL21713101 | 0.68 | FABP3 (0.40) | SMN1; SMN2KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL17267944 | 0.67 | ALDH1A1 (0.48) | SMN1; SMN2TP53KDM4EALDH1A1HPGD | |
| SCHEMBL4930739 | 0.66 | KMT2A (0.34) | SMN1; SMN2KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL9655129 | 0.65 | ALDH1A1 (0.46) | SMN1; SMN2KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL5511141 | 0.64 | NPSR1 (0.41) | SMN1; SMN2KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL1572504 | 0.64 | ALDH1A1 (0.45) | SMN1; SMN2TP53KDM4EALDH1A1KMT2A | |
| SCHEMBL2056999 | 0.64 | NPSR1 (0.53) | SMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946473-B2 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-11-06 | — | — | US | disclosed |
| EP-1279674-A2 | Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | American Cyanamid Company (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1157024-B1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | SI, TNF, PTDSS1 | SMN1; SMN2 1419/4885TP53 853/4885KDM4E 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.